Alexander's, Inc. exhibits a bifurcated financial profile: a 2026Q2 FFO spike to $163.6M (FFO/share of $31.84) appears non-recurring, while underlying revenue fell 5.8% YoY to $54.7M, reflecting persistent retail tenant churn in its concentrated NYC portfolio....
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | $3.02+0.7% vs $3.00 | $55M+1.1% vs $54M |
Q2 2026 May 4, 2026 | $2.60-15.6% vs $3.08 | $53M+0.0% vs $53M |
Q1 2026 Feb 9, 2026 | $2.43-19.5% vs $3.02 | $53M-0.3% vs $53M |
Q4 2025 Nov 3, 2025 | $2.91+16.4% vs $2.50 | $53M+0.0% vs $53M |
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease
Alexander's (NYSE: ALX - Get Free Report) and Tritax Big Box REIT (OTCMKTS:TTBXF - Get Free Report) are both real estate companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Earnings and Valuation This table compares
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.
Here is how Alexander's (ALX) and Healthpeak (DOC) have performed compared to their sector so far this year.
Benchmark ALX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Alexander's, Inc. (ALX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $243.83 | $1.25B | 44.33 | -5.83% | 13.24% | 19.74% | 7.38% | |
| $48.77 | $3.47B | -41.33 | 41.96% | -16.65% | -3.94% | — | |
| $33.56 | $6.31B | 7.99 | 1.27% | 3.71% | 1% | — | |
| $4.13 | $708.13M | 22.94 | 0.67% | 0.93% | 0.4% | — | |
| $6.60 | $1.46B | -31.43 | 1.97% | -13.47% | -2.39% | — | |
| $60.24 | $9.61B | 34.62 | 2.19% | 8.44% | 3.87% | — |
Alexander's, Inc. (ALX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Alexander's, Inc. (ALX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 28, 2026·SEC
May 21, 2026·SEC
Mar 31, 2026·SEC
Get notified when ALX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alexander's, Inc. (ALX) stock FAQ — growth, dividends, profitability & financials explained
Alexander's, Inc. (ALX) reported $214.8M in revenue for fiscal year 2025. This represents a 752% increase from $25.2M in 1996.
Alexander's, Inc. (ALX) saw revenue decline by 5.8% over the past year.
Yes, Alexander's, Inc. (ALX) is profitable, generating $169.8M in net income for fiscal year 2025 (13.2% net margin).
Yes, Alexander's, Inc. (ALX) pays a dividend with a yield of 7.38%. This makes it attractive for income-focused investors.
Alexander's, Inc. (ALX) has a return on equity (ROE) of 19.7%. This is reasonable for most industries.
Alexander's, Inc. (ALX) generated Funds From Operations (FFO) of $205.4M in the trailing twelve months. FFO is the primary profitability metric for REITs.
Alexander's, Inc. (ALX) offers a 7.38% dividend yield, which is attractive for income investors. REITs are required to distribute at least 90% of taxable income to shareholders.
